Redx Oncology staff dig deep to raise funds for Liverpool Cancer Research UK Centre

14 Jan 2013

Staff at a Liverpool cancer drug research centre have donated more than £1,000 to a local charity, after raising the money through their Christmas raffle.

Members of the team at Redx Oncology handed over a cheque for £1,020 to the Liverpool Cancer Research UK Centre at a special event on Friday, January 11th.

Redx Oncology is the first subsidiary of Redx Pharma, an early stage drug development company based in Liverpool. Redx Oncology, is a private-sector centre for pre-clinical research and novel anti-cancer drug development, which launched in April last year.

Dr Jason Parsons, Dr Carlos Rubbi, Prof John Neoptolemos, Dr Derek Lindsay, Amy Wilkinson & Claire Hutchinson

Dr Derek Lindsay, Managing Director at Redx Oncology, said: We’re delighted to be supporting such a worthwhile cause – the Liverpool Cancer Research UK Centre does world-class work which has a significant impact in tackling cancer.

The Redx team has done an amazing job to raise such a significant amount and we will no doubt continue to do all we can to support local charities.

The Liverpool Cancer Research UK Centre brings together scientists, doctors and nurses to boost key areas of research that will produce the greatest benefits for cancer patients in Liverpool, Merseyside and Cheshire. The Centre also focuses on tackling cancer in low income communities in the region, where more people die from the disease.

Professor John Neoptolemos, Head of Surgery and Oncology at the University of Liverpool and an international expert in the treatment of pancreatic cancer who works with the Liverpool Cancer Research UK Centre, accepted the cheque from Dr Lindsay on behalf of the charity.

Professor Neoptolemos said: The Liverpool CRUK Centre is incredibly grateful to be the recipient of Redx Pharma’s Christmas fundraising donation.

The level of funding needed to produce world class practice-changing research is enormous; therefore, donations like this one are vital.

Improving cancer prevention, diagnosis and treatment, underpinned by world class research and access to the latest therapies is the responsibility of many different organisations. Both the City of Liverpool and the Merseyside and Cheshire Region have the highest cancer mortality of any region in the UK and one of the worst in Europe.

This underlines the importance of the Liverpool Cancer Research UK Centre to bring local partners together in a common goal of reducing cancer mortality. The Liverpool CRUK Centre works closely with Redx Pharma to explore how links and relationships can be developed with its medicinal chemistry centre in Liverpool focusing in oncology.

The Liverpool Cancer Research UK Centre is a partnership between Cancer Research UK, the Royal Liverpool and Broadgreen University Hospitals NHS trust, Clatterbridge Centre of Oncology NHS Foundation Trust, the University of Liverpool, Liverpool City Council and the Merseyside and Cheshire Cancer Network.